Ippei Matsumoto
Overview
Explore the profile of Ippei Matsumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
2435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, et al.
Clin Mol Hepatol
. 2025 Mar;
PMID: 40065709
Background/aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in...
2.
Aoki T, Kudo M, Nishida N, Ueshima K, Tsuchiya K, Tada T, et al.
J Gastroenterol
. 2025 Mar;
PMID: 40055288
Background: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug discontinuation criteria remain unclear. This study aims...
3.
Nanno Y, Toyama H, Nagai K, Lee D, Uchida Y, Ishida J, et al.
Ann Gastroenterol Surg
. 2025 Mar;
9(2):339-346.
PMID: 40046526
Aim: Evidence regarding the reliability of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for assessing histological proliferation and WHO grading of small (≤20 mm) pancreatic neuroendocrine tumors (PanNETs) is limited. Methods: In...
4.
Ariake K, Mizuma M, Unno M, Satoi S, Yamamoto N, Hayashi M, et al.
J Hepatobiliary Pancreat Sci
. 2024 Sep;
32(1):69-81.
PMID: 39317950
Background: The aim of this study was to determine the optimal treatment for patients with pancreatic cancer (PaCa) having positive peritoneal cytology (PPC). Methods: This multicenter retrospective study included patients...
5.
Hirono S, Higuchi R, Honda G, Nara S, Esaki M, Gotohda N, et al.
Ann Gastroenterol Surg
. 2024 Sep;
8(5):845-859.
PMID: 39229554
Background: Surgical resection is standard treatment for invasive intraductal papillary mucinous carcinoma (IPMC); however, impact of multidisciplinary treatment on survival including postoperative adjuvant therapy (AT), neoadjuvant therapy (NAT), and treatment...
6.
Nobori C, Matsumoto I, Nakano M, Ami K, Yoshida Y, Lee D, et al.
Surg Today
. 2024 Sep;
PMID: 39222257
Purpose: To clarify the prevalence, risk factors, and clinical implications associated with zinc deficiency in patients undergoing pancreatic surgery. Methods: The serum zinc levels were measured in 329 patients post-pancreatic...
7.
Okano N, Kawai M, Ueno M, Yu X, Inoue Y, Takahashi S, et al.
J Hepatobiliary Pancreat Sci
. 2024 Aug;
31(11):816-829.
PMID: 39150050
Background: The efficacy and safety of conversion surgery (CS) after FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) chemotherapy in patients with initially unresectable pancreatic cancer (PC) remains unclear. Methods: This multicenter...
8.
Yabushita Y, Park J, Yoon Y, Ohtsuka M, Kwon W, Choi G, et al.
J Hepatobiliary Pancreat Sci
. 2024 May;
31(7):481-491.
PMID: 38822227
Background: Although surgical resection is the only curative treatment for biliary tract cancer, in some cases, the disease is diagnosed as unresectable at initial presentation. There are few reports of...
9.
Hijioka S, Yamashige D, Esaki M, Honda G, Higuchi R, Masui T, et al.
Clin Gastroenterol Hepatol
. 2024 Apr;
22(7):1416-1426.e5.
PMID: 38615727
Background & Aims: Despite previously reported treatment strategies for nonfunctioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs), uncertainties persist. We aimed to evaluate the surgically resected cases of nonfunctioning small...
10.
Okada K, Kimura K, Yamashita Y, Shibuya K, Matsumoto I, Satoi S, et al.
Ann Gastroenterol Surg
. 2023 Nov;
7(6):997-1008.
PMID: 37927936
Background: Nab-paclitaxel plus gemcitabine is a standard treatment for metastatic/locally advanced pancreatic cancer. The effectiveness of neoadjuvant therapy with nab-paclitaxel plus gemcitabine (GnP-NAT) in patients with borderline resectable pancreatic cancer...